Jane Street’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-87,481
Closed -$812K 12601
2025
Q4
$1.07M Buy
+87,481
New +$1.43M ﹤0.01% 5977
2025
Q1
Sell
-72,454
Closed -$443K 10284
2024
Q4
$352K Buy
72,454
+50,808
+235% +$284K ﹤0.01% 7465
2024
Q3
$167K Sell
21,646
-12,682
-37% -$113K ﹤0.01% 8757
2024
Q2
$343K Buy
34,328
+6,173
+22% +$67.8K ﹤0.01% 7590
2024
Q1
$342K Buy
+28,155
New +$408K ﹤0.01% 7341
2023
Q2
Sell
-126,652
Closed -$1.85M 9314
2023
Q1
$1.85M Buy
+126,652
New +$2.12M ﹤0.01% 3962
2022
Q2
Sell
-15,299
Closed -$453K 10520
2022
Q1
$577K Buy
15,299
+10,623
+227% +$470K ﹤0.01% 7195
2021
Q4
$290K Sell
4,676
-7,503
-62% -$569K ﹤0.01% 8226
2021
Q3
$1.04M Buy
12,179
+3,770
+45% +$237K ﹤0.01% 5824
2021
Q2
$521K Sell
8,409
-3,383
-29% -$172K ﹤0.01% 7158
2021
Q1
$575K Buy
+11,792
New +$569K ﹤0.01% 6551

Other funds holding OPRX

Jane Street's OPRX Position: Q1 2026 in Review

Jane Street sold out of OptimizeRx (OPRX) in Q1 2026, closing a stake of 87,481 shares — an estimated $812K sold.

Jane Street first reported a position in OPRX in Q1 2021 and held it in 11 quarters. The position peaked at $1.85M in Q1 2023. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Jane Street reported no remaining OptimizeRx position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 87,481 OptimizeRx shares in Q1 2026, an estimated $812K.
  • Jane Street first reported a position in OptimizeRx in Q1 2021 and held it in 11 quarters.
  • Jane Street's OptimizeRx position peaked at $1.85M in Q1 2023.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.